Albireo Pharma Inc.

Coming off the back of a challenging 2021 and 2022, many industry analysts cautiously forecast a bigger 2023, more deals, mergers and IPOs. While this has not happened, bar a few delicious morsels suc

Cholestatic liver disease, disorders related to slowing or stalling of the biliary system, have been fallback options for companies also working in the non-alcoholic steatohepatitis space, and two com

Ipsen SA has posted a reasonable set of third quarter financials, including the first sales of its recently approved ultra-rare disorder drug Sohonos, but growth plans for its bile acid modulator, By

In the last couple of years, through a combination of in-licensing and acquisitions, Ipsen SA has added 20 assets to its pipeline across its three focus areas of oncology, rare disease and neuroscie